$30M Private Placement for Femasys with Potential $90M Upside — Femasys Inc.

Event summary

$30M private placement led by Nantahala Capital, with additional investors including Rosalind Advisors and management team.
Deal includes sale of 9.4M shares of common stock and pre-funded warrants, plus accompanying warrants for up to 18.7M additional shares.
Potential proceeds could reach $90M if all warrants are exercised, contingent on revenue and share price milestones.
Closing expected around August 10, 2026, with Laidlaw & Company as placement agent and Lake Street Capital Markets as financial advisor.

The big picture

Femasys' $30M private placement, with potential for up to $90M in additional proceeds, underscores the growing interest in non-surgical fertility and birth control solutions. The deal highlights strategic shifts toward cost-effective, in-office procedures that expand access and improve care standards. This financing positions Femasys to accelerate its commercialization efforts and clinical trials, aligning with broader industry trends toward innovative reproductive health technologies.

What we're watching

Milestone Achievement: Whether Femasys can meet the specified revenue and share price milestones to trigger full warrant exercise.
Commercial Execution: The pace at which Femasys advances its fertility portfolio and FemBloc clinical/regulatory program in the U.S.
Market Confidence: How institutional investor participation reflects broader market confidence in Femasys' strategy and differentiated technologies.